Lithium citrate as treatment of canavan disease

Clinical Neuropharmacology

Volumn 35, Issue 3, 2012, Pages 150-151

  Edo Solsona, María Dolores ^a   Fernández, Laura Lorente ^a   Boquet, Emilio Monte ^a   Andrés, José Luís Poveda ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Canavan disease; lithium citrate; N acetylaspartate

Indexed keywords

LITHIUM; LITHIUM CITRATE; N ACETYLASPARTIC ACID;

ALERTNESS; ARTICLE; BASAL GANGLION; BRAIN REGION; CANAVAN DISEASE; CASE REPORT; CEREBRAL PALSY; DENTATE NUCLEUS; DISEASE COURSE; DRUG DOSE INCREASE; EYE TRACKING; FEMALE; GAS CHROMATOGRAPHY; GAZE; GENE MUTATION; HEAD MOVEMENT; HUMAN; INFANT; LITHIUM BLOOD LEVEL; LIVER FUNCTION; MACROCEPHALY; MASS SPECTROMETRY; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; MUSCLE TONE; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY OF LIFE; THALAMUS; THYROID FUNCTION; URINARY EXCRETION; WHITE MATTER;

CANAVAN DISEASE; CITRATES; FEMALE; HUMANS; INFANT; TREATMENT OUTCOME;

EID: 84861492300     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182515c9d     Document Type: Article

References (11)

1. O'Donnell T, Rozinger S, Nakashima TT, et al. Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphates in rat brain. Brain Res 2000;880:84Y91.
2. Janson CG, Assadi M, Francis J, et al. Lithium citrate for CanaVan disease. Pediatr Neurol 2005;33:235Y243.
3. Assadi M, Janson C, Wang DJ, et al. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in CanaVan disease. Eur J Paediatr Neurol 2010;14:354Y359.
4. Rubin Y, LaPlaca MC, Smith DH, et al. The effect of N-acetyl aspartate on the intracellular free calcium concentration in Tera2-neurons. Neuroendocrinol Lett 1995;198:209Y212.
5. Yan HD, Ishihara K, Serikawa T, et al. Activation by N-acetyl-L-aspartate of acutely dissociated hippocampal neurons in rate via metabotropic glutamate receptor. Epilepsia 2003;44(9):1153Y1159.
6. Pliss L, FitzGibbon T, Balcar V, et al. Neurotoxicity of NAAG in vivo is sensitive to NMDA antagonists and mGluR II ligands. Neuropharmacology and Neurotoxicology 2000;11(16):3651Y3654.
7. Pederzolli CD, Rockenbach FJ, Zanin FR, et al. Intracerebroventricular administration of N-acetylaspartic acid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats. Metab Brain Dis 2009;24(2):283Y298.
8. Chaleck-Franaszek E, Chuang D. Lithium activates the serine/threonine kinase Akt-1 and supresses the glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci 1999;96:8745Y8750.
9. Rowe MK. Chuang DM. Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med 2004;6(21):1Y18.
10. Hashimoto R, Hough C, Nakazawa T, et al. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002;80:589Y597.
11. Mersmann N, Tkachev D, Jelinek R, et al. Aspartoacylase-lacZ knockin mice: an engineered model of CanaVan disease. PloS One 2011;6(5):e20336.